The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The firm will use the award to develop silica nanomaterial for use with many sample types, including blood, cultured cells, and pathogens.
The company believes it can make oligonucleotide synthesis faster and cheaper than currently available methods, and plans to launch a platform in the next year.
The company is developing a cloud-based platform for the detection, quantification, and interpretation of alternative splicing variation from NGS data.
The technology will allow scientists or clinicians to load crude blood sample and generate DNA sequencing libraries in a fully automated workflow.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.